1. ZHAW digitalcollection
  2. School of Engineering
  3. Publikationen
  4. Publikationen School of Engineering
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFranzini, Anca-
dc.contributor.authorBaty, Florent-
dc.contributor.authorMacovei, Ina I.-
dc.contributor.authorDürr, Oliver-
dc.contributor.authorDroege, Cornelia-
dc.contributor.authorBetticher, Daniel-
dc.contributor.authorGrigoriu, Bogdan D.-
dc.contributor.authorKlingbiel, Dirk-
dc.contributor.authorZappa, Francesco-
dc.contributor.authorBrutsche, Martin H.-
dc.date.accessioned2018-12-17T08:18:28Z-
dc.date.available2018-12-17T08:18:28Z-
dc.date.issued2015-
dc.identifier.issn1078-0432de_CH
dc.identifier.issn1557-3265de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/13892-
dc.description.abstractPurpose: We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced non–small cell lung cancer (NSCLC) patients. Experimental Design: Whole-genome gene expression profiling was performed on 42 biopsy samples (from SAKK 19/05 trial) using Affymetrix exon arrays, and associations with the following endpoints: time-to-progression (TTP) under therapy, tumor-shrinkage (TS), and overall survival (OS) were investigated. Next, we performed gene set enrichment analyses using genes associated with the angiogenic process and hypoxia response to evaluate their predictive value for patients' outcome. Results: Our analysis revealed that both the angiogenic and hypoxia response signatures were enriched within the genes predictive of BE response, TS, and OS. Higher gene expression levels (GEL) of the 10-gene angiogenesis-associated signature and lower levels of the 10-gene hypoxia response signature predicted improved TTP under BE, 7.1 months versus 2.1 months for low versus high-risk patients (P = 0.005), and median TTP 6.9 months versus 2.9 months (P = 0.016), respectively. The hypoxia response signature associated with higher TS at 12 weeks and improved OS (17.8 months vs. 9.9 months for low vs. high-risk patients, P = 0.001). Conclusions: We were able to identify gene expression signatures derived from the angiogenesis and hypoxia response pathways with predictive value for clinical outcome in advanced nonsquamous NSCLC patients. This could lead to the identification of clinically relevant biomarkers, which will allow for selecting the subset of patients who benefit from the treatment and predict drug response. Clin Cancer Res; 21(23); 5253–63.de_CH
dc.language.isoende_CH
dc.publisherAmerican Association for Cancer Researchde_CH
dc.relation.ispartofClinical Cancer Researchde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectGene expressionde_CH
dc.subject.ddc572: Biochemiede_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleGene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non-small cell lung cancer patients (SAKK 19/05 trial)de_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Engineeringde_CH
zhaw.organisationalunitInstitut für Datenanalyse und Prozessdesign (IDP)de_CH
dc.identifier.doi10.1158/1078-0432.CCR-14-3135de_CH
dc.identifier.pmid25922429de_CH
zhaw.funding.euNode_CH
zhaw.issue23de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end5263de_CH
zhaw.pages.start5253de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume21de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen School of Engineering

Files in This Item:
There are no files associated with this item.
Show simple item record
Franzini, A., Baty, F., Macovei, I. I., Dürr, O., Droege, C., Betticher, D., Grigoriu, B. D., Klingbiel, D., Zappa, F., & Brutsche, M. H. (2015). Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non-small cell lung cancer patients (SAKK 19/05 trial). Clinical Cancer Research, 21(23), 5253–5263. https://doi.org/10.1158/1078-0432.CCR-14-3135
Franzini, A. et al. (2015) ‘Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non-small cell lung cancer patients (SAKK 19/05 trial)’, Clinical Cancer Research, 21(23), pp. 5253–5263. Available at: https://doi.org/10.1158/1078-0432.CCR-14-3135.
A. Franzini et al., “Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non-small cell lung cancer patients (SAKK 19/05 trial),” Clinical Cancer Research, vol. 21, no. 23, pp. 5253–5263, 2015, doi: 10.1158/1078-0432.CCR-14-3135.
FRANZINI, Anca, Florent BATY, Ina I. MACOVEI, Oliver DÜRR, Cornelia DROEGE, Daniel BETTICHER, Bogdan D. GRIGORIU, Dirk KLINGBIEL, Francesco ZAPPA und Martin H. BRUTSCHE, 2015. Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced nonsquamous non-small cell lung cancer patients (SAKK 19/05 trial). Clinical Cancer Research. 2015. Bd. 21, Nr. 23, S. 5253–5263. DOI 10.1158/1078-0432.CCR-14-3135
Franzini, Anca, Florent Baty, Ina I. Macovei, Oliver Dürr, Cornelia Droege, Daniel Betticher, Bogdan D. Grigoriu, Dirk Klingbiel, Francesco Zappa, and Martin H. Brutsche. 2015. “Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 Trial).” Clinical Cancer Research 21 (23): 5253–63. https://doi.org/10.1158/1078-0432.CCR-14-3135.
Franzini, Anca, et al. “Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 Trial).” Clinical Cancer Research, vol. 21, no. 23, 2015, pp. 5253–63, https://doi.org/10.1158/1078-0432.CCR-14-3135.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.